<DOC>
	<DOC>NCT01026116</DOC>
	<brief_summary>Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.</brief_summary>
	<brief_title>A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patients, age 18~40 Unilateral, operable, histologically confirmed adenocarcinoma of the breast Stage IIII Primary surgery with clear margins plus axillary dissection Able to start protocol Rx within 4 weeks of surgery HER2 positive (IHC 3+ OR FISH+) and sequential use of trastuzumab followed by chemotherapy Occult breast cancer with histologically confirmed primary invasive carcinoma or DICS with microinvasion in the ipsilateral breast after surgery ECOG performance status 01 Adequate cardiac, renal, hepatic and hematologic function Metastatic disease Bilateral breast cancer (synchronous or metachronous) Prior radiation therapy, hormonal therapy and chemotherapy for breast cancer Previous cancer (except treated basal cell and squamous cell carcinoma of the skin or cancer of the uterine cervix) HER2 positive (IHC 3+ OR FISH+) and concurrence use of adjuvant chemotherapy and trastuzumab Documented history of cardiac disease contradiction anthracyclines Concurrent serious illness Peripheral neuropathy of CTC grade&gt;1 History of hypersensitivity to drugs formulated in Cremophor EL polyoxyethylated castor oil), the vehicle used for commercial paclitaxel formulations Pregnancy or lactation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>